Applications

1690 – Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Closed
  • Pre-MSAC consultation Closed
  • Outcome Not supported

Application details

Reason for application

Highly Specialised Therapy- National Health Reform Agreement.

Service or technology in this application

Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T (CAR-T) cell therapy for treatment of patients with multiple myeloma (MM) who are refractory or have failed more than three lines of prior therapy. The therapy involves taking the patient’s own cells from peripheral blood, enriching them for T-cells (a type of white blood cell that is an essential part of the immune system) and genetically modifying them before infusing them back into the patient to treat the MM.

Type: Therapeutic technology

Medical condition this application addresses

Multiple Myeloma (MM) is a cancer affecting a type of white blood cell, known as a plasma cell. Plasma cells are found in the bone marrow and make up a part of the immune system. When cancerous, they accumulate to a point where there is not enough space left for normal, healthy blood cells to be produced. MM can cause bone disease, kidney problems, anaemia, increased risk of infection and blood-clotting.

Consultation survey and deadlines

  • PASC consultation: Closed
  • MSAC consultation: Closed Friday 10 June 2022

Meetings to consider this application

  • PASC meeting: 9–10 December 2021
  • ESC meeting: 9–10 June 2022
  • MSAC meeting: 28–29 July 2022